Franklin Genomic Ownership
| HELX Etf | USD 29.53 0.29 0.99% |
Please note, institutional investors have a lot of resources and new technology at their disposal. They can put in a lot of research and financial analysis when reviewing investment options. There are many different types of institutional investors, including banks, hedge funds, insurance companies, and pension plans. One of the main advantages they have over retail investors is the fees paid for trades. As they are buying in large quantities, they can manage their cost more effectively.
Franklin |
Franklin Etf Ownership Analysis
Franklin Genomic is is formed as Regulated Investment Company in the United States. ETF is managed and operated by Franklin Templeton Services, LLC. The fund has 66 constituents across multiple sectors and instustries. The fund charges 0.5 percent management fee with a total expences of 0.5 percent of total asset. The fund retains 98.96% of assets under management (AUM) in equities. Under normal market conditions, the fund invests at least 80 percent of its net assets in equity securities of companies that are relevant to its investment theme of genomic advancements. Franklin Genomic is traded on BATS Exchange in the United States. To learn more about Franklin Genomic Advancements call the company at NA.Sector Exposure (%)
Investors will always prefer to have their portfolios divercified against different sectors. The broad sector allocation increases the possibility of making a profit or at least avoiding a loss. However, this may also reduce the expected return on Franklin Etf. Generally, it depends on diversification level and type but usually, the broader the sector allocation, the less risk can be expected from holding Franklin Genomic , and the less return is expected.
Currency Exposure (%)
Investment Allocations (%)
Top Etf Constituents
| MEDP | Medpace Holdings | Stock | |
| VRTX | Vertex Pharmaceuticals | Stock | |
| VEEV | Veeva Systems Class | Stock | |
| TXG | 10X Genomics | Stock | |
| TMO | Thermo Fisher Scientific | Stock | |
| TDOC | Teladoc | Stock | |
| RGEN | Repligen | Stock | |
| REGN | Regeneron Pharmaceuticals | Stock | |
| QURE | Uniqure NV | Stock | |
| QGEN | Qiagen NV | Stock | |
| QDEL | Quidel | Stock | |
| NTRA | Natera Inc | Stock | |
| NTLA | Intellia Therapeutics | Stock | |
| MRNA | Moderna | Stock | |
| A | Agilent Technologies | Stock | |
| IQV | IQVIA Holdings | Stock | |
| ILMN | Illumina | Stock | |
| GH | Guardant Health | Stock | |
| EDIT | Editas Medicine | Stock | |
| DHR | Danaher | Stock | |
| CTVA | Corteva | Stock | |
| CTLT | Catalent | Stock | |
| CRSP | Crispr Therapeutics AG | Stock | |
| BRKR | Bruker | Stock | |
| BIO | Bio Rad Laboratories | Stock | |
| AVTR | Avantor | Stock |
Franklin Genomic Adv Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Franklin Genomic insiders, such as employees or executives, is commonly permitted as long as it does not rely on Franklin Genomic's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Franklin Genomic insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Transier William L over six months ago Acquisition by Transier William L of 1843 shares of Franklin Genomic subject to Rule 16b-3 |
Franklin Genomic Outstanding Bonds
Franklin Genomic issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Franklin Genomic Adv uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Franklin bonds can be classified according to their maturity, which is the date when Franklin Genomic Advancements has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Dana 575 percent Corp BondUS235822AB96 | View | |
| Volcan Compania Minera Corp BondUSP98047AC08 | View | |
| Boeing Co 2196 Corp BondUS097023DG73 | View | |
| MPLX LP 4875 Corp BondUS55336VAG59 | View | |
| MPLX LP 52 Corp BondUS55336VAL45 | View | |
| International Game Technology Corp BondUS460599AD57 | View | |
| BNP Paribas FRN Corp BondUSF1R15XK367 | View | |
| Morgan Stanley 3971 Corp BondUS61744YAL20 | View |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Franklin Genomic Adv offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Franklin Genomic's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Franklin Genomic Advancements Etf. Outlined below are crucial reports that will aid in making a well-informed decision on Franklin Genomic Advancements Etf:Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Franklin Genomic Advancements. Also, note that the market value of any etf could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis. You can also try the Fundamentals Comparison module to compare fundamentals across multiple equities to find investing opportunities.
The market value of Franklin Genomic Adv is measured differently than its book value, which is the value of Franklin that is recorded on the company's balance sheet. Investors also form their own opinion of Franklin Genomic's value that differs from its market value or its book value, called intrinsic value, which is Franklin Genomic's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Franklin Genomic's market value can be influenced by many factors that don't directly affect Franklin Genomic's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Franklin Genomic's value and its price as these two are different measures arrived at by different means. Investors typically determine if Franklin Genomic is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Franklin Genomic's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.